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430 Audit of hearing surveillance in UK paediatric cystic ﬁbrosis
units
J.D. Wilkinson1, J. Mora2. 1Cystic Fibrosis Unit, RHSC Yorkhill Hospital,
Glasgow, United Kingdom; 2Department of Paediatric Audiology, RHSC Yorkhill
Hospital, Glasgow, United Kingdom
Background: Aminoglycosides may be associated with ototoxicity. Children with
CF may require several courses of aminoglycosides per year. Although drug
levels are monitored, published data suggests that some patients show enhanced
susceptibility to aminoglycoside ototoxicity at normal serum levels. We conducted
a postal Questionnaire, sent to 27 large Paediatric CF Centres in the UK, to gain
information on audiological screening procedures.
Results:22 Centres responded. All Centres reported using IV aminoglycosides. Au-
diological screening was being carried out at all Centres to some degree. 9/22 (41%)
Centres reported having an established protocol in place for audiological screening.
2 Centres carried out baseline hearing tests prior to IV aminoglycoside treatment.
8 (36%) Centres carried out regular hearing tests at least annually in patients
receiving Tobramycin. 11 (50%) Centres performed “as required” audiological
assessment for reasons such as high drug levels, symptoms of ototoxicity or at
transplantation referral. 5 Centres carried out testing at the request of patient
or parents. 16 (73%) of Centres stated that they always provide information to
families about potential ototoxicity of aminoglycosides. 4 Centres provide written
drug information. 12 Centres provide verbal information only.
Conclusion: IV aminoglycosides are used widely within the UK CF Paediatric
setting. CF Centre protocols for audiological screening are present in less than
half of the Centres responding to this Audit. Drug information about potential
ototoxicity is provided by most Centres, although only a small minority provide
written information. There seems to be a lack of consensus regarding audiological
screening procedures and methods of information sharing.
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Cystic ﬁbrosis (CF) is an autosomal recessive disease characterised by increased
viscosity of mucus secretions and high chloride concentration in exocrine secretions.
Vitamin A deﬁciency is a common manifestation in CF. The ocular manifestations
of hypovitaminosis A are conjunctival and corneal xerosis, keratomalacia including
ulceration, night-blindness, severe loss of visual acuity, and ﬂecked retina.
The aim of this report is to describe a youngest patient presenting with corneal
opacity and diagnosed as CF.
Case report: A eleven-month-old male infant was referred for assessment of
diarrhea, cough, abdominal distantion, vomit, and failure to thrive. On physical
examination his weight and height were below the ﬁfth percentile for age. Marked
wasting of muscle mass was noted. Subcutan lipoid tissue was decreased, skin
was pale. Ocular examination demonstrated that visual acuity was limited to hand
motion for each eye. Marked conjunctival hyperemia with dry and keratinized
epithelium was present bilaterally. Bilateral corneal opacity was demonstrated.
Laboratory abnormalities included hemoglobin 7.8 g/dl (normal: 11.1−13.1 g/dl),
wbc 25,000/mm3, vitamin A: 20.2mg/dl (30−60mg/dl), vitamin E: 0.49mg/dl
(0.8−1.5mg/dl). Serum Zinc level was normal. Sweat chloride was elevated at
72mEq/L (normal <60mEq/L). The corneal opacity resolved within 2 months
of starting pancreatic enzyme, nutritional supplementation vitamin A intake with
a daily supplement of 5000 IU/day, and vitamin E 100 IU/day. Molecular genetic
studies revealed a homozygote DF508 genotype, conﬁrming cystic ﬁbrosis.
Conclusion: Corneal opacity could be seen in CF patients due to hypovitaminosis A.
And in corneal lesions CF should be considered for differential diagnosis.
432 Cost saving potential in pharmaceutical treatment of adult
patients with cystic ﬁbrosis
C.T. Baltin1, C. Smaczny1, T.O. Wagner1. 1Pneumology/Allergology, J. W. Goethe
University, Frankfurt, Germany
Background: Several studies have identiﬁed medication expenses as a major cost
driver for the treatment of CF. The present study builds on these studies by
conducting in-depth analyses of the saving potential from alternative drugs within
the entire medication portfolio.
Objective: The study aims to increase transparency on cost saving potential to
maintain a high level of symptomatic treatment for patients with CF. Results
will help to develop opportunities to optimize the medication portfolio within the
ﬁnancially tightening pharmaceutical treatment of CF-patients.
Method: Analyses are based on the daily drug intake of adult patients (n = 124)
from the CF outpatient department in Frankfurt, Germany for the entire year of
2007. A total of 424 different drugs were classiﬁed and separately analyzed using
ABDATA database to determine lower-priced substitutes.
Results: Cost saving potential has been identiﬁed for 260 out of the 424 drugs
(61%). Reclusive substitution of the top 30 cost-intensive drugs shows a re-
duction of annual medication costs for the entire patient sample of €44.960
(1.6%), with highest incentives for a substitution of “Zinnat® 250 (Cefuroxime)”,
“Augmentan® 875/125 (Amoxicillin & Clavulanic acid)”, as well as “Zithromax®
250 (Azithromycin)”. The largest amount of annual costs is caused by medication
group “oral antibiotics & antiinfectiva”. It accounts for approx. €1.14 million, which
could be lowered by €38.205 (3.3%) using substitutes at a lower price if applicable.
Furthermore, realizing the cost saving potential across the four most expensive
medication groups reveals annual savings of €76.658 (2.8%).
Outlook: Realizing the cost saving potential can optimize the medication portfolio
and enhance sustainable medical care for patients with CF.
433 Creatinine clearance in cystic ﬁbrosis patients: MDRD,
Cockcroft-Gault and measured creatinine clearance
I. Bronsveld1, L.H. Conemans1, E.A. van de Graaf1, J.W. Lammers1, F. Teding
van Berkhout1. 1University Medical Centre Utrecht, Utrecht, Netherlands
It is known that CFTR is expressed in the kidney, however it is not clear whether
aberrant or absent CFTR leads to loss of renal function in CF. Earlier investigations
did report on secondary renal dysfunction caused by nephrotoxic effects of CF
drugs, such as aminoglycosides. To investigate renal disease in CF we were
searching for an easier but accurate alternative to measured creatinine clearance
to address renal function.
In this study we tested the accuracy of the abbreviated Modiﬁcation of Diet in
Renal Disease (aMDRD) and Cockcroft-Gault (CG) compared to the measured
creatinine clearance (mCCL). Therefore, we included the measurements on collected
24-hours urine samples of CF patients admitted to the hospital for IV antibiotics
and the measured creatinine clearances performed during screening sessions for
lung transplantation. This resulted in a total of 35 measurements.
We ﬁrst divided the group in patients with normal renal function (mCCL
>80ml/min) and those with a diminished renal function (mCCL< 80ml/min). In
both groups, there was a strong correlation between the mCCL and aMDRD,
and between the mCCL and CG results. Momentarily, we are enlarging our study
with patients with severely impaired kidney function, to test correlations between
estimated and measured values in lower ranges of creatinine clearance.
In conclusion we have found that aMDRD and CG have good correlations with
measured creatinine clearance. We found biases and ranges of error in CF patients
with diminished renal function that are acceptable (data not shown in abstract).
Thus, in this population the aMDRD and CG formulas can be used in CF patients,
also in those with diminished creatinine clearance, to determine renal function.
